| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0008 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.001 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.001 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.092 | 0.002 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |